Replimune Group, Inc.

Replimune is a biotech company focused on revolutionizing cancer treatment with a new class of oncolytic immunotherapies intended to activate a powerful and durable full-body anti-tumor response. Its mission is to revolutionize cancer treatment through comprehensive activation of a tumor-specific immune response, potentially treating a broad range of cancer types. Its first therapy, TUDRIQEV, is an oncolytic immunotherapy administered in combination with nivolumab for patients with advanced melanoma that have progressed on an anti-PD-1 containing regimen, and it is now FDA approved. The company states that since 2015 it has been pushing for breakthroughs in cancer care.

Replimune is a biotech company advancing novel oncolytic immunotherapies intended to ignite a systemic immune response and potentially treat a broad range of difficult-to-treat cancers. The company states that since 2015 it has been pushing for the breakthrough that changes what a cancer diagnosis means to patients. Its first therapy, TUDRIQEV, is an oncolytic immunotherapy administered in combination with nivolumab for patients with advanced melanoma that have progressed on an anti-PD-1 containing regimen, and it is now FDA approved.

Pioneering a novel class of oncolytic immunotherapies intended to kill the tumor locally, alter the tumor microenvironment, and ignite a powerful anti-tumor immune response.

• TUDRIQEV

  An oncolytic immunotherapy administered in combination with nivolumab for patients with advanced melanoma that have progressed on an anti-PD-1 containing regimen; now FDA approved.

1. 1Oncolytic Immunotherapies | Replimunereplimune.com
2. 2Transforming Cancer Treatment | Replimunereplimune.com
3. 3Replimune Group, Inc. (United States)wikidata.org